Genflow's SIRT6 gene therapy met its endpoint in old beagles

Genflow Biosciences said on 8 September 2026 that its SLAB trial had met its primary endpoint. SLAB — Sarcopenia and Longevity in Aged Beagles — was a randomised, blinded study in 24 beagles over ten years old, split across two naked-DNA dose cohorts, a single-dose AAV8 cohort, and a saline control.

The therapy delivers the centenarian variant of SIRT6, a gene linked to unusually long human lifespan. The endpoint was a reduction in biological age read by the GRIM methylation clock, which estimates ageing from chemical marks on DNA. Genflow reports that treated animals showed a clear signal of improvement relative to controls, and that improvements also appeared across several functional and observable secondary measures.

The company released no numbers with the announcement. Detailed results, including the mechanistic analyses, are to be presented at the Animal Longevity Summit in Toronto on 2 October 2026 — so the size of the effect is not yet public, only its direction.

Genflow frames the result as strengthening its position with animal-health licensing partners. Its human-facing work continues separately, in a trial of GF-1002 in metabolic dysfunction-associated steatohepatitis.